Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 549-555

  Yamamoto, Hirofumi ^a   Tei, Mitsuyoshi ^a   Uemura, Mamoru ^a   Takemasa, Ichiro ^a   Uemura, Yoshio ^b   Murata, Kohei ^c   Fukunaga, Mutsumi ^d   Ohue, Masayuki ^e   Ohnishi, Tadashi ^f   Ikeda, Kimimasa ^g   Kato, Takeshi ^h   Okamura, Shu ^c   Ikenaga, Masakazu ⁱ   Haraguchi, Naotsugu ^a   Nishimura, Junichi ^a   Mizushima, Tsunekazu ^a   Mimori, Koshi ^j   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^c Suita Municipal Hospital   (Japan)

^d Sakai City Medical Center   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f OSAKA POLICE HOSPITAL   (Japan)

^g Minoh City Hospital   (Japan)

^h KANSAI ROSAI HOSPITAL   (Japan)

ⁱ OSAKA NATIONAL HOSPITAL   (Japan)

^j KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Colorectal cancer; Ephrin A1; Hypoxia; Prognosis

Indexed keywords

EPHRIN A1; MESSENGER RNA; SMALL INTERFERING RNA;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION;

AGED; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPHRIN-A1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84873658823     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1750     Document Type: Article

References (34)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR and Buchler MW: Colorectal cancer. Lancet 365: 153-165, 2005.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
3. Roberts RB, Arteaga CL and Threadgill DW: Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 5: 115-120, 2004.
4. Semenza GL: Hypoxia and cancer. Cancer Metastasis Rev 26: 223-224, 2007.
5. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
6. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
7. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
9. Vihanto MM, Plock J, Erni D, Frey BM, Frey FJ and Huynh-Do U: Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. FASEB J 19: 1689-1691, 2005.
10. Yamashita T, Ohneda K, Nagano M, et al: Hypoxia-inducible transcription factor-2alpha in endothelial cells regulates tumor neovascularization through activation of ephrin A1. J Biol Chem 283: 18926-18936, 2008.
11. Holzman LB, Marks RM and Dixit VM: A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol 10: 5830-5838, 1990.
12. Bartley TD, Hunt RW, Welcher AA, et al: B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 368: 558-560, 1994.
13. Brantley DM, Cheng N, Thompson EJ, et al: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011-7026, 2002.
14. Pandey A, Shao H, Marks RM, Polverini PJ and Dixit VM: Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268: 567-569, 1995.
15. Deroanne C, Vouret-Craviari V, Wang B and Pouyssegur J: EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. J Cell Sci 116: 1367-1376, 2003.
16. Cheng N, Brantley DM, Liu H, et al: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1: 2-11, 2002.
17. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL and Pasquale EB: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 6043-6052, 2000.
18. Abraham S, Knapp DW, Cheng L, et al: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12: 353-360, 2006.
19. Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D and Chen J: Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 66: 10315-10324, 2006.
20. Noblitt LW, Bangari DS, Shukla S, et al: Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 11: 757-766, 2004.
21. Nakamura R, Kataoka H, Sato N, et al: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 96: 42-47, 2005.
22. Liu DP, Wang Y, Koeffler HP and Xie D: Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK. Int J Oncol 30: 865-871, 2007.
23. Nasreen N, Mohammed KA, Lai Y and Antony VB: Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Cancer Lett 258: 215-222, 2007.
24. Uemura M, Yamamoto H, Takemasa I, et al: Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. Clin Cancer Res 16: 4636-4646, 2010.
25. Yamamoto H, Kondo M, Nakamori S, et al: JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 125: 556-571, 2003.
26. Okami J, Yamamoto H, Fujiwara Y, et al: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 5: 2018-2024, 1999.
27. Nagel S, Schmidt M, Thiede C, Huhn D and Neubauer A: Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). Nucleic Acids Res 24: 4102-4103, 1996.
28. Hayashi N, Yamamoto H, Hiraoka N, et al: Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 34: 638-650, 2001.
29. Takemasa I, Yamamoto H, Sekimoto M, et al: Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res 60: 3043-3050, 2000.
30. Holm R, De Putte GV, Suo Z, Lie AK and Kristensen GB: Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int J Med Sci 5: 121-126, 2008.
31. Potla L, Boghaert ER, Armellino D, Frost P and Damle NK: Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett 175: 187-195, 2002.
32. Brennan DJ, Jirstrom K, Kronblad A, et al: CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12: 6421-6431, 2006.
33. Kizaka-Kondoh S, Inoue M, Harada H and Hiraoka M: Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94: 1021-1028, 2003.
34. Noda T, Yamamoto H, Takemasa I, et al: PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int 32: 110-118, 2012.